Date: September 8, 2022                                      Administrative Circular: 2022:36

ATTN: Medical Health Officers and Branch Offices  
      Public Health Nursing Administrators and Assistant Administrators  
      Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,  
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility
Content related to First Booster Dose and Second Booster Dose has been replaced with the Fall 2022 Booster Dose Program.

Please remove page numbers: 1-3 dated August 26, 2022
Please add new page numbers: 1-3 dated September 8, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) Pediatric (Orange Vial Cap)
Content has been added under Special Considerations to indicate that COVID-19 booster doses may be deferred in those who have tested positive for COVID-19 (by PCR or rapid antigen test) until 3-6 months from symptom onset or, for asymptomatic cases, from the time of the positive test as per NACI.

Please remove page numbers: 1-5 dated August 26, 2022
Please add new page numbers: 1-5 dated September 8, 2022

COVID-19 mRNA Vaccine Spikevax™ Bivalent (Moderna)

- A new biological product page has been developed for Spikevax™ Bivalent (Moderna).
- This vaccine is supplied with a royal blue vial cap and green label border.

Please add new page numbers: 1-4 dated September 8, 2022
The following COVID-19 vaccine product pages have been updated to indicate the following:

- **Doses and Schedules:**
  - First and second booster dose content has been replaced with the fall booster dose program.
  - The minimum interval between any previous booster dose and the fall booster dose is 3 months.
  - Booster dosing for the Moderna monovalent COVID-19 vaccine is now aligned for all booster dose indications (i.e., 50 mcg).

- **Booster Doses:** Content has been updated to include the fall booster dose program. There is no longer a preferential recommendation for the use of Pfizer-BioNTech Comirnaty as a booster dose in those 18-29 years of age due to increased risk of myocarditis. Per NACI, post-market safety surveillance data to date indicate that the risk of myocarditis following a booster dose is lower compared to that following the second dose in the primary series, and current data do not show a product-specific difference in the risks of myocarditis and/or pericarditis after a booster dose of an mRNA COVID-19 vaccine. Individuals in this age group can receive a booster dose with any available mRNA COVID-19 vaccine for which they are currently eligible.

- **Special Considerations:** Content has been revised to indicate that COVID-19 booster doses may be deferred in those who have tested positive for COVID-19 (by PCR or rapid antigen test) until 3-6 months from symptom onset or, for asymptomatic cases, from the time of the positive test as per NACI.

**COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Gray Vial Cap)**

- Please remove page numbers: 1-6 dated July 29, 2022
- Please add new page numbers: 1-5 dated September 8, 2022

**COVID-19 Vaccine Comirnaty® (Pfizer-BioNTech) Adult/Adolescent (Purple Vial Cap)**

- Please remove page numbers: 1-6 dated July 29, 2022
- Please add new page numbers: 1-5 dated September 8, 2022

**COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 Years of Age and Older (Red Vial Cap)**

- Please remove page numbers: 1-5 dated August 8, 2022
- Please add new page numbers: 1-5 dated September 8, 2022
The following COVID-19 vaccine product pages have been updated to indicate the following:

- **Doses and Schedules**: Booster and second booster dose content has been replaced with the fall booster dose program.
- **Booster Doses**:
  - Content has been updated to include the fall booster dose program.
  - The minimum interval between any previous booster dose and the fall booster dose is 3 months.
- **Special Considerations**: Content has been revised to indicate that COVID-19 booster doses may be deferred in those who have tested positive for COVID-19 (by PCR or rapid antigen test) until 3-6 months from symptom onset or, for asymptomatic cases, from the time of the positive test as per NACI.

**COVID-19 Vaccine VAXZEVRIA™ (AstraZeneca)**

COVISHELL has been removed as this product is no longer authorized for use in Canada. Content has been added to indicate that the AstraZeneca product is currently unavailable in Canada.

Please remove page numbers: 1-4 dated July 8, 2022
Please add new page numbers: 1-4 dated September 8, 2022

**COVID-19 Vaccine (Ad26.COV2.S [recombinant]) JCOVDEN™ (Janssen Inc.)**

Please remove page numbers: 1-4 dated July 8, 2022
Please add new page numbers: 1-4 dated September 8, 2022

**COVID-19 Vaccine NUVAXOVID™ (Novavax)**

Please remove page numbers: 1-3 dated July 8, 2022
Please add new page numbers: 1-3 dated September 8, 2022

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated August 2022, and replace with the enclosed updated Title Page and Table of Contents dated September 2022.
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division